Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-16
DOI
10.1007/s40257-021-00603-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti‐TNF treatment during pregnancy and birth outcomes: A population‐based study from Denmark, Finland, and Sweden
- (2020) Gabriella Bröms et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
- (2020) Alice Gottlieb et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study in Paediatric Patients with Moderate‐to‐Severe Plaque Psoriasis (IXORA‐PEDS)
- (2020) A.S. Paller et al. BRITISH JOURNAL OF DERMATOLOGY
- Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study
- (2020) S. Philipp et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?
- (2020) Matteo Megna et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans
- (2020) James D. Chambers et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- COVID-19 and immunomodulator/immunosuppressant use in dermatology
- (2020) Kyla N. Price et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic
- (2020) Marilyn T. Wan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Should biologics for psoriasis be interrupted in the era of COVID-19?
- (2020) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
- (2020) L. Puig et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
- (2020) Philip J Mease et al. LANCET
- Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
- (2020) Atul Deodhar et al. LANCET
- Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
- (2020) Iain B McInnes et al. LANCET
- SARS-CoV-2 and COVID-19: The most important research questions
- (2020) Kit-San Yuen et al. Cell and Bioscience
- Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
- (2020) Amy Kunchok et al. JAMA Neurology
- Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Nicholas D. Brownstone et al. Dermatology and Therapy
- Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial
- (2020) R.B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic
- (2020) Maha N. Syed et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- May IL-17 have a role in COVID-19 infection?
- (2020) Matteo Megna et al. MEDICAL HYPOTHESES
- One-Year Pharmacovigilance Update of Brodalumab
- (2020) Mark Lebwohl et al. Journal of Drugs in Dermatology
- Prevalence of Psoriasis Among Adults in the U.S. 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys
- (2020) Jeffrey Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic
- (2020) Maha N. Syed et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis
- (2019) C. Phan et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
- (2019) Stephen Hanauer et al. Journal of Crohns & Colitis
- Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
- (2019) Stefan Schreiber et al. ANNALS OF THE RHEUMATIC DISEASES
- US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
- (2019) Bruce E. Strober et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Management of Pediatric Plaque Psoriasis using Biologics
- (2019) Perla Lansang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives
- (2019) Clara De Simone et al. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA
- Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease
- (2019) Joshua Korzenik et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations
- (2019) Stefano Piaserico et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
- (2019) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions
- (2019) Martin Diebold et al. Multiple Sclerosis and Related Disorders
- Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
- (2019) Mark G. Lebwohl et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
- (2019) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
- (2019) Gerd R. Burmester et al. ADVANCES IN THERAPY
- Exposure to Infliximab During Pregnancy: Post-Marketing Experience
- (2019) Anja Geldhof et al. DRUG SAFETY
- Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini‐review with a representative case report
- (2019) M. Venturini et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Psoriatic arthritis: From pathogenesis to pharmacologic management
- (2019) Rossella Talotta et al. PHARMACOLOGICAL RESEARCH
- Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study
- (2019) Christina D. Chambers et al. PLoS One
- Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
- (2019) Désirée van der Heijde et al. RHEUMATOLOGY
- Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
- (2019) April Armstrong et al. Dermatology and Therapy
- Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
- (2019) Lun-Fei Liu et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
- (2019) José María G. Ruiz de Morales et al. AUTOIMMUNITY REVIEWS
- Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: A nine-year multicenter cohort study
- (2019) Hsien-Yi Chiu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
- (2019) Akbar K Waljee et al. Lancet Gastroenterology & Hepatology
- Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study
- (2018) H Chiu et al. ACTA DERMATO-VENEREOLOGICA
- Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
- (2018) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
- (2018) R. B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab
- (2018) Sze-Wen Ting et al. CLINICAL DRUG INVESTIGATION
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
- (2018) J.W. Baddley et al. CLINICAL MICROBIOLOGY AND INFECTION
- Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
- (2018) Florenzo Iannone et al. CLINICAL RHEUMATOLOGY
- Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab
- (2018) Marco Galluzzo et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2018) Zenas Z.N. Yiu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
- (2018) Scott M. Whitlock et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
- (2018) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
- (2018) Farzad Alinaghi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
- (2018) Mark Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
- (2018) Alice B. Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pediatric psoriasis: Evolving perspectives
- (2018) Lawrence F. Eichenfield et al. PEDIATRIC DERMATOLOGY
- Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
- (2018) Alice B Gottlieb et al. RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database
- (2018) Megan E. B. Clowse et al. Arthritis & Rheumatology
- Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis
- (2018) C. Leonardi et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient
- (2018) Girum T. Assefa et al. JOURNAL OF DERMATOLOGY
- Incidence and risk of inflammatory bowel disease in patients with psoriasis – a nationwide 20-year cohort study
- (2018) Alexander Egeberg et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
- (2018) Giuseppina Caiazzo et al. Frontiers in Immunology
- Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C
- (2018) S.A.R. Siegel et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
- (2018) Paul Rutgeerts et al. GASTROENTEROLOGY
- Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
- (2018) Lieven Pouillon et al. INFLAMMATORY BOWEL DISEASES
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- (2018) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
- (2017) Pablo Olivera et al. INFLAMMATORY BOWEL DISEASES
- Old and New Biological Therapies for Psoriasis
- (2017) Kirsten Rønholt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment strategies for psoriatic arthritis
- (2017) Julien Schemoul et al. JOINT BONE SPINE
- Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study
- (2017) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
- (2017) Igor Snast et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population
- (2017) Maryam M. Asgari et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis and multiple sclerosis - hidden link?
- (2017) U. Gieler JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial
- (2017) Kim Papp et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
- (2017) Arthur Kavanaugh et al. ARTHRITIS CARE & RESEARCH
- Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zheng Zhang et al. BMJ Open
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA
- (2016) Aoibhlinn O’Toole et al. DIGESTIVE DISEASES AND SCIENCES
- “Just in Time”: When Is It Safe to Administer Live Vaccines to Infants Exposed to Anti-Tumor Necrosis Factor Agents In Utero?
- (2016) Cynthia H. Seow et al. GASTROENTEROLOGY
- Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study
- (2016) Alexander Egeberg et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
- (2016) Eva Havrdová et al. JOURNAL OF NEUROLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis
- (2016) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Risk of Cancer in Patients With Psoriasis
- (2016) Zelma C. Chiesa Fuxench et al. JAMA Dermatology
- Management of chronic hepatitis B in severe liver disease
- (2016) James Fung et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry
- (2015) L Dreyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
- (2015) Fabrizio Cantini et al. AUTOIMMUNITY REVIEWS
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
- (2015) S.C. Heslinga et al. CURRENT MEDICINAL CHEMISTRY
- Pregnancy during Ustekinumab Treatment for Severe Psoriasis
- (2015) Katiucia Rocha et al. DERMATOLOGY
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
- (2015) Ian Landells et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations
- (2015) Shunsuke Mori WORLD JOURNAL OF GASTROENTEROLOGY
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- Psoriasis and risk of heart failure: a nationwide cohort study
- (2014) Usman Khalid et al. EUROPEAN JOURNAL OF HEART FAILURE
- Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease
- (2013) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
- (2013) Paweł Kawalec et al. Archives of Medical Science
- The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
- (2013) H.-Y. Chiu et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti–tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis
- (2013) Kiran Motaparthi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
- (2013) Jeremy Hugh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies
- (2013) C. Pouplard et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey
- (2013) Raphaèle Seror et al. RHEUMATOLOGY
- The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
- (2012) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study
- (2012) Meng-Sui Lee et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
- (2012) Maria A. Lopez-Olivo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
- (2011) X. Mariette et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials
- (2011) Erica D. Dommasch et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
- (2011) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- (2010) Johan Askling et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-α–Blocker Therapy
- (2009) Pierre Lozeron et al. ARCHIVES OF NEUROLOGY
- Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case–Control Analysis
- (2009) Yolanda B. Brauchli et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Screening for tuberculosis infection prior to initiation of anti-TNF therapy
- (2008) Ajit Lalvani et al. AUTOIMMUNITY REVIEWS
- Inflammatory demyelinating events following treatment with anti-tumor necrosis factor
- (2008) A. Fromont et al. CYTOKINE
- Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study
- (2008) Nynne Nyboe Andersen et al. Journal of Crohns & Colitis
- National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents
- (2008) Sean D. Doherty et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
- (2008) Amy S. Paller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started